In glioma, increased SHMT2 expression was found to be critical for cancer cell survival and adaptation to the ischaemic tumour microenvironment (TME)64, a response that made cancer cells dependent on glycine decarboxylase (GLDC) to prevent the accumulation of excess glycine. The gene discussed is SHMT2; the disease is cancer.